AI Precision Medicine stocks on X

AI Precision Medicine stocks trending on X

AI- and data-driven platforms turning genomics, biomarkers, and longitudinal clinical evidence into personalised diagnostics and targeted therapies. Companies positioned as 'biology ontologies' — Tempus AI (exome-grade tumor profiling), Guardant Health (liquid biopsy), Hims & Hers (consumer health as a data platform) — rather than single-drug pipelines. Distinct from the biotech strategy (clinical drug developers) and gene-editing (CRISPR/base/prime editing): this is the data and diagnostics layer rebuilding healthcare around AI.

AI Precision Medicine stocks trending on X

Top stocks by X chatter

Hims & Hers Health, Inc.$HIMS

Medical - Equipment & Services

$28.15-2.16%

1Y-40.3%

3,481 posts-3%

Bullish sentiment

Hims is riding a strong post-earnings mood — $753M revenue vs $700M expected, 300k+ net subscriber adds, raised full-year guide to $3.2B, and Needham and BofA both hiking price targets. Bulls are excited about the peptide opportunity, the Novo Wegovy-pill launch and the international ramp from the Eucalyptus deal. The bear channel is small but sharp: an EPS miss driven by legal contingencies, GLP-1 gross-margin compression from 79% to 64%, and a fresh round of Lilly retatrutide lawsuits. The dominant vibe is that the growth story is intact and the sell-off into the print was overdone.

Proven numbers

Hims & Hers is the telehealth-plus-pharmacy platform, best known for the direct-to-consumer weight-loss and men's-health SKUs it's built into a real subscription business. The last few quarters have been about scaling the operational base while the GLP-1 opportunity re-shapes; the tape has been about legal overhang. • The Q2 growth story is real: revenue of $753M grew 38% YoY, subscribers hit 2.9M (up 19%), and the raised full-year guide of $3.1-3.3B implies growth acceleration, not a slowdown — international revenue up 1,641% is a small-base number but a genuinely new leg. • The legal wall is thick, though: at least five separate law-firm shareholder-investigation press releases dropped this week alone, layered on top of active FTC litigation, which is why the stock is 40% off its 12-month high despite fundamentals that would normally re-rate it higher. • The balance sheet has a new twist that the crowd hasn't fully priced: a $400M JPMorgan receivables-purchase facility was signed July 1, which turns pharmacy receivables into cash faster but also introduces a factoring cost — a working-capital positive that's not free. The Nov 2 print has to keep the 38% growth cadence and margin trajectory to overpower the legal drag; if instead the FTC action or one of the securities suits gets any real traction, the fundamentals stop mattering and the multiple compresses to whatever settlement math the market decides on.

ImmunityBio, Inc.$IBRX

Biotechnology

$7.57-1.05%

1Y+179.3%

489 posts-8%

Bullish sentiment

ImmunityBio chatter is bullish and platform-thesis heavy. The dominant catalyst is hiring former World Bank President Jim Yong Kim as Vice Chairman — bringing global-health / sovereign-wealth / BlackRock-infra connections to global ANKTIVA rollout. ANKTIVA is already approved in 34 countries; Q2 revenue $50.7M (+92% YoY), H1 $94.8M (+121% YoY). Speculation about IBRX acquiring NWBO plus Saudi/UAE regulatory tailwinds. Short interest just dropped 5.4M shares. The tape is 'transitioning from R&D story to global commercialization story' with no bear voice in-window.

Driven by hype

ImmunityBio is a small-cap biotech commercializing ANKTIVA, its IL-15 immunotherapy for bladder cancer and now expanding into other indications globally. The story just moved from clinical to commercial: Q2 was a real product-revenue print and the company hired former World Bank president Jim Yong Kim as Vice Chairman. • Q2 was a genuine commercial print: net product revenue of $50.7M grew 92% YoY and H1 revenue of $94.8M was up 121% — this is the first year the equity trades on actual sales rather than clinical milestones. • Regulatory footprint is expanding fast: ANKTIVA is now approved in 34 countries, with UAE approval landing in late July — the global rollout is what the Kim appointment is meant to accelerate. • Cambridge Equities disclosed a 24.7% stake via 13D/A August 6 — one holder controlling a quarter of the company is a real anchor buyer, though also a supply overhang if intentions shift. • Position at 54% of 52w, essentially flat vs the 50d MA — the +244% YTD move has been sequential, not parabolic, so accumulation still has room. November 3 is the next print — a fifth straight beat plus expanded ex-US revenue commentary extends the compounding; any commercial-execution stumble on ANKTIVA reimbursement or a Cambridge Equities partial exit is the invalidator. The real risk is that transitioning from R&D to commercial requires operational muscle biotechs often lack.

NeoGenomics, Inc.$NEO

Medical - Diagnostics & Research

$15.94-2.75%

1Y+157.1%

417 posts+15%

Bullish sentiment

$NEO chatter is entirely about the Neo blockchain (not NeoGenomics). Posts are uniformly promotional: 10-year mainnet milestone, Neo X EVM upgrades including a GovPaymaster for free txs, developer 'Proof of Working' rewards, and ecosystem AMAs. Community narrative frames it as superior to ETH/SOL in 2026.

Proven numbers

NeoGenomics is a specialty cancer diagnostics company — comprehensive-genomic-profiling tests, minimal-residual-disease monitoring, and pharma-services clinical trial support. It's a mid-cap healthcare-services name that's hit 52-week highs on execution acceleration. The X chatter under $NEO is entirely about the Neo blockchain, not this equity. Where the actual equity stands: • Q2 was a clean beat: revenue of $201.7M grew 11% year-over-year with EPS of $0.05 beating $0.03 by 49% — pharma-services is compounding faster than clinical services, and gross margin expanded to 45.6% from 39.8% two quarters ago, the operating-leverage flip that turns diagnostics from slow-growth into a compounding story. • The valuation looks stretched but the growth math supports it: 54x trailing EV/EBITDA is high, but consensus models revenue growing from $800M this year to $965M by 2028 with EPS from $0.18 to $0.46 — the multiple has to come in through earnings compounding rather than expansion. • The executive-departure signal is worth watching: an unnamed officer departure disclosed August 11 plus a settlement disclosed July 20 — combined with insider selling from officer Greg Aunan ($321K on August 4), the C-suite is showing ambient signal that deserves attention alongside 52-week-high enthusiasm. The story extends as long as Q3 pharma-services growth stays above 15% and gross margin holds above 44%. What flips it: a large pharma-services customer loss, or the executive-departure pattern extending to CFO/CEO transition. Ignore the Neo blockchain chatter.

Tempus AI, Inc.$TEMRising on

Medical - Healthcare Information Services

$52.10-4.03%

1Y-27.2%

299 posts+8%

Bullish sentiment

Tempus AI chatter is bullish on the multimodal AI-plus-clinical-data thesis. PRISM2 (Nature Medicine paper trained on 2.3M pathology slides, 700k reports, 14M clinical data points — via Paige acquisition) is the anchor catalyst; Google still holds TEM shares. 2026 revenue guide $1.595-1.605B (+25% YoY), Q3 $405-410M, targeting ~$65M adj EBITDA. Distribution-decides-who-wins thesis: 'Tempus solved the shelf first.' The stock is building a Stage-1 base with a $274K Nov 80-call print. No bear voice; the tape is 'more attention on this company the better.'

Heartflow, Inc. Common Stock$HTFL

Medical - Healthcare Information Services

—

1Y—

124 posts

PendingInsufficient posts on X for reliable sentiment analysis.

Prime Medicine, Inc.$PRME

Biotechnology

$3.09-2.52%

1Y-15.1%

107 posts+32%

Bullish sentiment

Prime Medicine chatter is emphatically bullish. Anchor catalysts: FDA granted RMAT designation to lead program in June, binding arbitration with Beam Therapeutics resolved in PRME's favor in July, first in vivo therapy cleared US IND, Aug 6 10-Q established a confirmed going-concern position and no share dilution. USPTO published PRME's cystic-fibrosis prime-editing application. A 72-page institutional research report titled 'Prime Medicine: Platform Validation at the Inflection' generated buzz. Speculation that PRME is the undisclosed 'leading Gene Editing company' in the ReCode CFTR collaboration. No bear voice.

Veeva Systems Inc.$VEEVStrong Fundamentals

Software - Application

$243.75-3.52%

1Y-11.4%

105 posts+15%

Bullish sentiment

Veeva Systems traders frame it as the AI-in-healthcare pick — long-term price targets around $600, recurring subscription revenue over 80% of the mix, and a plan to scale from ~$2.4B today to $6B by end of decade. Grok lists it among the biggest anonymized healthcare-data holders alongside IQV, UNH, and TEM. One technician calls out a possible 6-month head-and-shoulders reversal, but the long-term bull thesis dominates the thin sample.

Personalis, Inc.$PSNL

Medical - Diagnostics & Research

$14.04-2.64%

1Y+201.3%

78 posts-9%

Bullish sentiment

Personalis is bullish tied to the $TEM $1.5B acquisition. Posters flag the spread at ~10% ($14.7 vs an equivalent $16.25 mix of cash and TEM), the deal is called cheap vs a $20B growing MRD TAM validated by NTRA. Long-term framing is TEM+PSNL as an oncology-behemoth 10-bagger with post-dilution fair value >$100.

Guardant Health, Inc.$GH

Medical - Diagnostics & Research

$157.21-1.46%

1Y+160.5%

75 posts-5%

Bullish sentiment

Guardant Health is strongly bullish. +76% over 3 months and +210% over past year, testing 52-week high of $176, base recovery with heavy institutional accumulation. Bullish IBD signal triggered, near-ATH entries, and framed as a top genomics/AI-application-layer pick alongside NTRA/TWST/ARKG.

GeneDx Holdings Corp.$WGS

Medical - Healthcare Information Services

$78.08-1.35%

1Y-36.5%

71 posts+5%

Bullish sentiment

GeneDx sentiment is bullish: +100% since initial recommendation 3 months ago, +6.5% intraday with September call buying, inverse H&S breakout. Framed alongside XGN, STLN, PSNL as bio winners.

Tango Therapeutics, Inc.$TNGX

Biotechnology

$25.60-0.19%

1Y+269.9%

65 posts+35%

Bullish sentiment

Tango Therapeutics posts are strongly bullish on the vopimetostat + daraxonrasib combo — 92% ORR in MTAP-deleted RAS-mutant PDAC, Stifel and Mizuho both at $40 PT/Buy, models pointing to $4.8B peak PDAC sales. Multiple upcoming 2H26 readouts (NSCLC monotherapy, TNG456 in GBM) not yet in models. ~42% short float noted as fuel.

Relay Therapeutics, Inc.$RLAY

Biotechnology

$19.86-0.35%

1Y+485.8%

58 posts+6%

Bullish sentiment

Relay Therapeutics is strongly bullish. Citizens PT raised to $26 from $21 (Market Outperform) and Guggenheim PT $26 (Buy) on zovega Ph3 execution, YE Ph3 enrollment update expected, pooled ~40% of Ph3-size data giving confidence. Perceptive Advisors increased holding 44.66% to 6.4% ownership. YTD +143.47%, from $3 to $20.

CareDx, Inc$CDNA

Medical - Diagnostics & Research

$45.32-4.35%

1Y+283.4%

44 posts+11%

Bullish sentiment

CareDx is bullish. Top 1-month relative strength in Deepvue Leaders screen, ETF-component tear alongside BFLY/TWST/GH/NTRA/TXG, holding above 21DMA with expanding volume signaling absorption/accumulation. Squeeze potential 8/21 $50 calls at $0.40. Some insider selling this week noted as a caution.

GE HealthCare Technologies Inc.$GEHCHot on

Medical - Healthcare Information Services

$73.69-0.14%

1Y+0.0%

43 posts+21%

Bullish sentiment

GE HealthCare is bullish after Q2 — adjusted EPS $1.13 vs $1.04 est, revenue $5.3B beat, and organic orders growth of 11.1% marked a record quarter with a book-to-bill of 1.15x and a $23.9B backlog. Stock popped 10-11% and management reaffirmed FY guidance. Pharmaceutical Diagnostics (+15.6%) and Advanced Imaging (+7.9%) lead; the drag is Patient Care Solutions revenue down 13.3% with negative EBIT, where the company is reviewing strategic options.

Nano-X Imaging Ltd.$NNOX

Medical - Devices

$0.998+1.29%

1Y-77.8%

19 posts-48%

Mixed sentiment

Nano-X Imaging news is dominated by a dilutive $8M registered direct offering priced at-the-market, and users note the Teledyne/Varex Imaging $1.1B deal as a positive sector read-through. NNOX also touts optimizing its medical-imaging AI framework for Intel Core Ultra processors with OpenVINO. Tone is neutral to modestly bullish on the tech but wary on the raise.

Azenta, Inc.$AZTA

Medical - Instruments & Supplies

$33.38-1.56%

1Y+9.1%

16 posts+20%

Bullish sentiment

Azenta traders are booking 16-33% returns on the August $35 calls at $0.60-$0.80 following a double beat, price-target upgrades and a gap-fill play setup. Options momentum is uniformly constructive and there are no bearish voices in the sample.

IQVIA Holdings Inc.$IQV

Medical - Diagnostics & Research

$236.66-2.01%

1Y+25.0%

14 posts+8%

Bullish sentiment

IQVIA's Q2 print was a beat-and-guide-in-line — EPS $3.15 vs $3.03 (+$0.12), revenue beat with guidance raised on the back of stronger R&D bookings. IQV is being pitched as one of four public companies with the biggest collections of anonymized healthcare data (alongside UNH, VEEV and TEM). MEDP is being called a positive read-through for IQV within the CRO/tools basket. There's no bearish voice in this window.

BillionToOne, Inc.$BLLNStrong Fundamentals

Medical - Diagnostics & Research

$93.33-0.76%

1Y-14.3%

12 posts0%

Bearish sentiment

Bullion — likely referring to a biotech name — got taken out to the woodshed post-Q2. One holder calls it 'a clear I am moving on from this name signal' and another 'overreaction of the ages,' but the mood is disappointed: revenue grew just 0.9% QoQ reported (7.3% ex-true-up), management barely acknowledged the weakness, and 40% drop feels crazy for a company growing 50% annually. Value hunters are stepping in citing 'oncology only' thesis with 'under 100 a steal,' but the crowd is bruised.

IDEAYA Biosciences, Inc.$IDYA

Biotechnology

$36.30-1.04%

1Y+49.0%

12 posts-52%

Bullish sentiment

IDEAYA Biosciences posters cheer Cantor upgrading views on the NCCN-listing strategy potentially bypassing Phase 3 for reimbursement, plus DLL3 ADC (IDE849) picking up steam with dual updates coming — Hengrui China trial at ESMO (10/23-27 Madrid) and IDEAYA's global trial in SCLC/NEC. $1.2B cash gives runway. Sentiment is decisively bullish on the pipeline breadth and regulatory-flexibility.